Study | TKI | EGFR mutations (n) | ORR (TKI vs CT) (%) | Median PFS (TKI vs CT) (months) | OS (TKI vs CT) (months/HR) |
---|---|---|---|---|---|
First-Signal | Gefitinib | 27 | 84 vs 37 | 8.4 vs 6.7 | 30.6 vs 26.5 |
IPASS | Gefitinib | 132 | 71 vs 47 | 9.8 vs 6.4 | 21.6 vs 21.9 |
NEJGSG002 | Gefitinib | 228 | 74 vs 29 | 10.8 vs 5.4 | 27.7 vs 26.6 |
WJTOG3405 | Gefitinib | 172 | 62 vs 32 | 9.2 vs 6.3 | NA |
OPTIMAL | Erlotinib | 154 | 83 vs 36 | 13.7 vs 4.6 | NA |
EURTACC | Erlotinib | 173 | 58 vs 15 | 9.7 vs 5.2 | NA |
Lux-Lung 3 | Afatinib | 308 | 56 vs 23 | 13.6 vs 6.9 | HR: 1.12 |
Lux-Lung 6 | Afatinib | 364 | 67 vs 23 | 11 vs 5.6 | HR: 0.95 |
CT, chemotherapy; EGFR, epidermal growth factor receptor; HR, hazard ratio; NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.